Subscribe to this collection to receive daily e-mail notification of new additions

	Title	Author(s)	Issue Date
	Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies Journal:European Journal of Cancer	Shahnam, AdelHitchen, NadiaNindra, UditManoharan, SathyaDesai, JayeshTran, BenSolomon, BenjaminLuen, Stephen JHui, RinaHopkins, Ashley MSorich, Michael J	18-Dec-2023
	Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522 Journal:Annals of Oncology	Pusztai, LDenkert, CO’Shaughnessy, JCortes, JDent, RMcArthur, HKummel, SBergh, JPark, YHHui, RHarbeck, NTakahashi, MUntch, MFasching, PACardoso, FZhu, YPan, WTryfonidis, KSchmid, P	16-Feb-2024
	Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826) Journal:European Journal of Cancer	Hamilton, EMeisel, JAlemany, CVirginia, BLin, NWesolowski, RMathauda-Sahota, GMakower, DLawrence, JFaltaos, DMitri, ZSabanathan, DClark, DPluard, THui, RMcCarthy, NPatel, M	1-Oct-2022
	Asbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation Journal:Asia-Pacific Journal of Clinical Oncology	Hyland, Rebecca A.Chrzanowska, AgataHannaford-Turner, KirstyDavis, AlexanderKe, HelenBradbury, LaurenNagrial, AdnanMcCaughan, BrianHui, Rinavan Zandwijk, NicoTakahashi, KenKao, Steven C.	2022
	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer Journal:New England Journal of Medicine	Schmid, PeterCortes, JavierDent, RebeccaPusztai, LajosMcArthur, HeatherKümmel, SherkoBergh, JonasDenkert, CarstenPark, Yeon HeeHui, RinaHarbeck, NadiaTakahashi, MasatoUntch, MichaelFasching, Peter A.Cardoso, FatimaAndersen, JayPatt, DebraDanso, MichaelFerreira, MartaMouret-Reynier, Marie AngeIm, Seock AhAhn, Jin HeeGion, MariaBaron-Hay, SallyBoileau, Jean FrançoisDing, YuTryfonidis, KonstantinosAktan, GurselKarantza, VassilikiO'Shaughnessy, Joyce	2022
	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials Journal:JNCI Cancer Spectrum	Man, JohnathanMillican, JaredMulvey, ArthurGebski, ValHui, Rina	2021
	Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing Journal:Breast Cancer Research and Treatment	Dinh, PhuongGraham, J. DinnyElder, Elisabeth N.Kabir, MasruraDoan, Tram B.French, JamesMeybodi, FaridHui, RinaWilcken, Nicholas R.Harnett, Paul R.Hsu, JeremyStuart, Kirsty E.Wang, TimAhern, VerityBrennan, MeaganFox, Stephen B.Dear, Rachel F.Lim, ElgeneWhite, MichelleMann, G. BrucePathmanathan, Nirmala	2022
	Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ‡ 50% Journal:Journal of Clinical Oncology	Reck, MartinRodríguez-Abreu, DelvysRobinson, Andrew G.Hui, RinaCsöszi, TiborFülöp, AndreaGottfried, MayaPeled, NirTafreshi, AliCuffe, SineadO’Brien, MaryRao, SumanHotta, KatsuyukiLeal, Ticiana A.Riess, Jonathan W.Jensen, ErinZhao, BinPietanza, M. CatherineBrahmer, Julie R.	2021
	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) Journal:Clinical Lung Cancer	Socinski, Mark A.Özgüroğlu, MustafaVillegas, AugustoDaniel, DaveyVicente, DavidMurakami, ShujiHui, RinaGray, Jhanelle E.Park, KeunchilVincent, MarkMann, HelenNewton, MichaelDennis, Phillip A.Antonia, Scott J.	2021
	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189 Journal:Annals of Oncology	Rodríguez-Abreu, D.Powell, S. F.Hochmair, M. J.Gadgeel, S.Esteban, E.Felip, E.Speranza, G.De Angelis, F.Dómine, M.Cheng, S. Y.Bischoff, H. G.Peled, N.Reck, M.Hui, R.Garon, E. B.Boyer, M.Kurata, T.Yang, J.Pietanza, M. C.Souza, F.Garassino, M. C.	2021
	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors Journal:Lung Cancer	Liu, JiaItchins, MalindaNagrial, AdnanCooper, Wendy A.De Silva, MadhawaBarnet, MeganVarikatt, WinnySivasubramaniam, VanathiDavis, AlexanderGill, Anthony J.Blinman, PrunellaLee, KennethHui, RinaGao, BoPavlakis, NickClarke, StephenLee, JennyBoyer, MichaelKao, Steven	2021
	Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time? Journal:Journal for ImmunoTherapy of Cancer	Ahern, ElizabethSolomon, Ben J.Hui, RinaPavlakis, NickO'Byrne, KenHughes, Brett G.M.	2021
	CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care Journal:Asia-Pacific Journal of Clinical Oncology	Hui, Rinade Boer, RichardLim, ElgeneYeo, BelindaLynch, Jodi	2021
	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer Journal:Future Oncology	Garassino, Marina C.Paz-Ares, LuisHui, RinaFaivre-Finn, CorinneSpira, AlexPlanchard, DavidÖzgüroǧlu, MustafaDaniel, DaveyVicente, DavidMurakami, ShujiLanger, CoreySenan, SureshSpigel, DavidRydén, AnnaZhang, YiduoO'brien, CathyDennis, Phillip A.Antonia, Scott J.	2021
	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC) Journal:Lung Cancer	Faivre-Finn, CorinneSpigel, David R.Senan, SureshLanger, CoreyPerez, Bradford A.Özgüroğlu, MustafaDaniel, DaveyVillegas, AugustoVicente, DavidHui, RinaMurakami, ShujiPaz-Ares, LuisBroadhurst, HelenWadsworth, CatherineDennis, Phillip A.Antonia, Scott J.	2021
	Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio Journal:Breast	Lee, Clara InkyungLow, Siew KeeMaldonado, RicardoFox, PeterBalakrishnar, BavanthiCoulter, Sallyde Bruijn, PeterKoolen, Stijn L.W.Gao, BoLynch, JodiZdenkowski, NicholasHui, RinaLiddle, ChristopherMathijssen, Ron H.J.Wilcken, NicholasWong, MarkGurney, Howard	2020
	Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy Journal:Endocrinology, Diabetes and Metabolism Case Reports	Herle, PratimaBoyages, StevenHui, RinaNahar, NajmunNgui, Nicholas K.	2020
	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial Journal:Clinical Breast Cancer	Chan, ArleneMoy, BeverlyMansi, JanineEjlertsen, BentHolmes, Frankie AnnChia, StephenIwata, HirojiGnant, MichaelLoibl, SibylleBarrios, Carlos H.Somali, IsilSmichkoska, SnezhanaMartinez, NoeliaAlonso, Mirta GarciaLink, John S.Mayer, Ingrid A.Cold, SørenMurillo, Serafin MoralesSenecal, FrancisInoue, KenichiRuiz-Borrego, ManuelHui, RinaDenduluri, NeelimaPatt, DebraRugo, Hope S.Johnston, Stephen R.D.Bryce, RichardZhang, BoXu, FengWong, AlvinMartin, Miguel	2021
	Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial Journal:Annals of Oncology	Paz-Ares, L.Spira, A.Raben, D.Planchard, D.Cho, B. C.Özgüroğlu, M.Daniel, D.Villegas, A.Vicente, D.Hui, R.Murakami, S.Spigel, D.Senan, S.Langer, C. J.Perez, B. A.Boothman, A. M.Broadhurst, H.Wadsworth, C.Dennis, P. A.Antonia, S. J.Faivre-Finn, C.	2020
	Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer Journal:Asia-Pacific Journal of Clinical Oncology	de Boer, RichardHui, RinaLim, ElgeneYeo, BelindaZdenkowski, Nicholas	2020